IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by National Bank of Canada FI

National Bank of Canada FI grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 98.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 62,436 shares of the company's stock after acquiring an additional 30,952 shares during the quarter. National Bank of Canada FI owned about 0.08% of IDEXX Laboratories worth $31,544,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Chicago Partners Investment Group LLC raised its position in IDEXX Laboratories by 16.7% during the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after purchasing an additional 96 shares during the period. Oppenheimer Asset Management Inc. boosted its stake in IDEXX Laboratories by 13.8% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock worth $5,825,000 after buying an additional 1,453 shares during the period. National Pension Service increased its position in IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company's stock valued at $93,957,000 after acquiring an additional 12,647 shares during the last quarter. EFG Asset Management Americas Corp. increased its position in IDEXX Laboratories by 45.3% during the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock valued at $6,201,000 after acquiring an additional 3,966 shares during the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after acquiring an additional 2,241 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the business's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.18% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Barclays cut their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Leerink Partners started coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an "outperform" rating and a $500.00 target price for the company. Piper Sandler restated a "neutral" rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. reduced their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $539.63.

IDEXX Laboratories Stock Up 3.4 %

Shares of NASDAQ:IDXX traded up $14.99 during trading hours on Monday, hitting $450.68. The company's stock had a trading volume of 783,785 shares, compared to its average volume of 512,364. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The firm's fifty day moving average price is $443.38 and its 200 day moving average price is $473.39. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a market capitalization of $36.91 billion, a price-to-earnings ratio of 43.46, a P/E/G ratio of 3.98 and a beta of 1.37.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the prior year, the business earned $2.53 earnings per share. IDEXX Laboratories's revenue was up 6.6% on a year-over-year basis. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.